Effects of Frankincense Compounds on Infection, Inflammation, and Oral Health

Cassio Luiz Coutinho Almeida-Da-Silva  
*University of the Pacific, csilva2@pacific.edu*

Nallusamy Sivakumar  
*College of Science, Sultan Qaboos University*

Homer Asadi  
*University of the Pacific*

Anna Chang-Chien  
*University of the Pacific*

M. Walid Qoronfleh  
*Qatar Foundation*

*See next page for additional authors*

Follow this and additional works at: https://scholarlycommons.pacific.edu/dugoni-facarticles

Part of the Dentistry Commons

**Recommended Citation**

Almeida-Da-Silva, C. L., Sivakumar, N., Asadi, H., Chang-Chien, A., Qoronfleh, M. W., Ojcius, D. M., & Essa, M. M. (2022). Effects of Frankincense Compounds on Infection, Inflammation, and Oral Health. *Molecules*, 27(13), 1–19. DOI: 10.3390/molecules27134174  
https://scholarlycommons.pacific.edu/dugoni-facarticles/852

This Article is brought to you for free and open access by the All Faculty Scholarship at Scholarly Commons. It has been accepted for inclusion in All Dugoni School of Dentistry Faculty Articles by an authorized administrator of Scholarly Commons. For more information, please contact mgibney@pacific.edu.
Authors
Cassio Luiz Coutinho Almeida-Da-Silva, Nallusamy Sivakumar, Homer Asadi, Anna Chang-Chien, M. Walid Qoronfleh, David M. Ojcius, and Musthafa Mohamed Essa

This article is available at Scholarly Commons: https://scholarlycommons.pacific.edu/dugoni-facarticles/852
Review

Effects of Frankincense Compounds on Infection, Inflammation, and Oral Health

Cássio Luiz Coutinho Almeida-da-Silva, Nallusamy Sivakumar, Homer Asadi, Anna Chang-Chien, M. Walid Qoronfleh, David M. Ojcius and Musthafa Mohamed Essa

Special Issue
Discovery of Bioactive Ingredients from Natural Products II
Edited by
Dr. Simona Fabroni, Dr. Krystian Marszalek and Dr. Aldo Todaro

https://doi.org/10.3390/molecules27134174
**Review**

**Effects of Frankincense Compounds on Infection, Inflammation, and Oral Health**

Cássio Luiz Coutinho Almeida-da-Silva 1,†, Nallusamy Sivakumar 2,†, Homer Asadi 1, Anna Chang-Chien 3, M. Walid Qoronfleh 4, David M. Ojcius 1,* and Musthafa Mohamed Essa 5

1 Department of Biomedical Sciences, Arthur A. Dugoni School of Dentistry, University of the Pacific, 155 Fifth Street, San Francisco, CA 94103, USA; csilva2@pacific.edu (C.L.C.A.-d.-S.); hasadi@pacific.edu (H.A.)
2 Department of Biology, College of Science, Sultan Qaboos University, Muscat 123, Oman; apniva@squ.edu.om
3 Dental Surgery Program, Arthur A. Dugoni School of Dentistry, University of the Pacific, 155 Fifth Street, San Francisco, CA 94103, USA; a_changchien@u.pacific.edu
4 Research & Policy Department, World Innovation Summit for Health (WISH), Qatar Foundation, Doha 0974, Qatar; walidq3@gmail.com
5 Department of Food Science and Nutrition, CAMS, Sultan Qaboos University, Muscat 123, Oman; drmdessa@gmail.com
* Correspondence: dojcius@pacific.edu
† These authors contributed equally to this work.

**Abstract:** Boswellia trees, found throughout the Middle East and parts of Africa and Asia, are the source of frankincense oil. Since antiquity, frankincense has been traded as a precious commodity, but it has also been used for the treatment of chronic disease, inflammation, oral health, and microbial infection. More recently, the bioactive components of *Boswellia* trees have been identified and characterized for their effects on cancer, microbial infection (especially infection by oral pathogens), and inflammation. Most studies have focused on cell lines, but more recent research has also investigated effects in animal models of disease. As natural products are considered to be safer than synthetic drugs, there is growing interest in further developing the use of substances such as frankincense oil for therapeutic treatment.

**Keywords:** inflammation; oral health; frankincense; infection; microbiology; immunology

**1. Introduction**

The increasing rate of antibiotics drug resistance, the cost of drugs, and the lack of access to healthcare systems for many people [1,2], especially in less developed countries, support the need for studying traditional medicines for sustainable, cost-effective therapeutic purposes. Frankincense is one of the common sources for traditional medicine [3]. The word “frankincense” is derived from an old French term “franc encens” and means “pure incense” or “pure and noble high-quality incense”. [4] Traditionally, frankincense gum has been burned for the pleasant fragrance it produces. It can be produced as a hardened resin or gum-like material discharged by the *Boswellia sacra* Flück. tree through cuts made in the trunk. Figure 1 shows the *B. sacra* tree, a member of the *Boswellia* genus. Frankincense has been traded and used as one of the most valuable materials since the beginning of written history [5].

The *Boswellia* genus includes around thirty species and is usually found in the arid regions of tropical Africa, the Arabian Peninsula, and South Asia [6], where moisture is supplied by morning mist. For example, *Boswellia serrata* Roxb. is found in India, *Boswellia sacra* in the Arabian Peninsula, *Boswellia papyrifera* (Caill. ex Delile) Hochst. and *Boswellia riveae* Engl. in Ethiopia, *Boswellia neglecta* S.Moore in Eritrea, and *Boswellia carterii* and *Boswellia frereana* Birdw. in North Africa and Somalia [7]. However, frankincense is obtained mostly from *B. frereana*, *B. sacra*, *B. papyrifera*, and *B. serrata*, which grow in Somalia,
Yemen, Oman, India, and Pakistan [8]. Although many *Boswellia* species are known to produce frankincense, *B. serrata* (India), *B. sacra* (Oman), and *B. carterii* (Somalia) are the major sources of commercial frankincense [9]. Table 1 includes a comprehensive list of all species of *Boswellia* trees as of 17 June 2022, according to The World Flora Online [10], and their geographical distribution [11].

![Boswellia sacra in Wadi Dawkah, a natural park of frankincense-producing trees in Oman. Boswellia sacra photo from Wikimedia.org.](image)

The oleoresin from the *Boswellia* trees has been considered as a treasure for more than a millennium due to its aromatic and medicinal applications [4]. Frankincense resin is secreted as a milky-white, sticky liquid when the plant is injured, and it is also known as olibanum [12]. Olibanum is produced mainly by four different species of Boswellia, which are *B. serrata*, *B. carterii*, *B. frereana*, and *B. sacra* [12,13]. The oleo gum resin produced by members of the genus *Boswellia* helps the plant defend against various infections and pests [14] and has been used in religious ceremonies, perfume production, and as a phytomedicine since antiquity [15]. Recently, the essential oils derived from frankincense are gaining high economic importance internationally for aromatherapy and perfumery [16].

For the present review, the PubMed database, Google Scholar database, Google database, the “Britannica” website, Science Direct, and “The World Flora Online” website were searched using terms that included “frankincense”, “boswellic acids”, and “frankincense and oral pathogens”. Exclusion criteria were non-English-language papers. With the present review, we aim to summarize the most recent research on the effects of frankincense compounds on microbial infection and inflammatory diseases. The effects of frankincense compounds on oral microbial infection are a focus of this review since there is a strong link between systemic and oral health [17].
Table 1. List of the current scientific name, official tree name, synonyms, geographical distribution, and references according to the “The World Flora Online website”.

| Current Scientific Name | Official Tree Name | Synonyms | Geographical Distribution | References |
|-------------------------|--------------------|----------|---------------------------|------------|
| Boswellia sacra         | Boswellia sacra    | Flueck.  | Arabian Peninsula (Oman, Yemen) | [18] |
|                        |                    |          |                           |            |
| Boswellia serrata       | Boswellia serrata  | Roxb. Ex Celebr. | India | [19] |
|                        |                    |          |                           |            |
| -                      | Boswellia odorata  | Hutch.  | Niger, northern Nigeria, and eastern Cameroon | [20] |
| -                      | Boswellia popoviana | Hepper  | Socotra  | [21] |
| -                      | Boswellia ruspoliana | Eng.    | Ethiopia, Somalia, Kenya | [22] |
| Boswellia socotrana     | Boswellia socotrana | Balf.f. | Socotra  | [23] |
| -                      | Boswellia holstii  | Eng.    | Ethiopia, Somalia, Kenya  | [24] |
| -                      | Boswellia microphylla | Chiov. | Ethiopia, Somalia, Kenya  | [25] |
| -                      | Boswellia multifoliolata | Eng. | Ethiopia, Somalia, Kenya  | [26] |
| Boswellia nana          | Boswellia nana    | Hepper  | Socotra  | [27] |
| Boswellia ogadensis     | Boswellia ogadensis | Vollesen | Ethiopia  | [28] |
| Boswellia ovalifoliolata | Boswellia ovalifoliolata | N.P.Balakr. & A.N.Henry | - | India | [29] |
| Boswellia pirottae      | Boswellia pirottae | Chiov.  | Ethiopia  | [30] |
| Boswellia ameero        | Boswellia ameero  | Balf.f. | Socotra  | [31] |
| -                      | Boswellia boranensis | Eng. | Ethiopia, Somalia, Kenya  | [32] |
| -                      | Boswellia brichettii | (Chiov.) Chiov. | - |            | [33] |
| -                      | Boswellia bullata | Thulin  | Socotra  | [34] |
| -                      | Boswellia chariensis | Guillaumin | - | Ethiopia, Eritrea, Sudan | [35] |
| -                      | Boswellia dioscoridis | Thulin | - | Socotra  | [36] |
| Boswellia elongata      | Boswellia elongata | Balf.f. | Socotra  | [37] |
| Boswellia freerana      | Boswellia freerana | Birdw.  | Somalia  | [38] |
| -                      | Boswellia globosa  | Thulin  | Somalia  | [39] |
| Boswellia dalzieli      | Boswellia dalzieli | Hutch.  | Northern Nigeria  | [40] |
| Ambilobea madagascariensis | Ambilobea madagascariensis (Capuron) Thulin, Beier & Razafim. | | | |
| -                      | Boswellia madagascariensis | Capuron | | Madagascar | [41] |
Table 1. Cont.

| Current Scientific Name | Official Tree Name | Synonyms | Geographical Distribution | References |
|-------------------------|--------------------|----------|---------------------------|------------|
| Garuga floribunda       | Garuga floribunda Decne. |          | Southern China, Bhutan, Bangladesh, India, through southeast Asia to the Pacific Islands | [42]        |
| Boschella papyrifera    | Boswellia papyrifera (Caill. Ex Delile) Hochst. | Amyris papyrifera Caill. ex Delile Boswellia occidentalis Engl. | Ethiopia | [43]        |
| Boschella rivae         | Boschella rivae Engl. | -        | Ethiopia, Somalia, Kenya | [44]        |
| Boschella hildebrandtii | Boschella hildebrandtii Engl. | -        | Ethiopia, Somalia, Kenya | [45]        |
| Boschella neglecta      | Boschella neglecta S.Moore. | -        | Eritrea | [47]        |

WFO: The World Flora Online.

2. Description of Frankincense Resins, Oils, and Boswellic Acids

The resin is available in yellowish, bluish, and greenish shades, and is composed of 3–8% volatile oils containing various terpenes and sesquiterpenes, 60–70% resin, and 27–35% gum [48]. In the mid-twentieth century, it was found that the gum contains two types of polysaccharides [49]. More recently, the composition showed that the monosaccharides present were predominantly galactose, arabinose, and glucuronic acid, along with small amounts of rhamnose and glucose [50]. However, recent scientific advancements allow us to identify the molecular content of diverse frankincense products such as incense mixtures, components of conventional medicines, and archaeological specimens.

The concentrated volatile, aromatic liquid obtained from different parts of the plant such as roots, seeds, leaves, flowers, and resins is called an essential oil. Mostly, a distillation process is used to extract the essential oil from Boschella plants [51]. The main chemical constituents of frankincense oil are pentacyclic triterpenoids [52], tetracyclic triterpenoids [53], and a variety of other oils [54]. The most common characteristic and intensely studied component in frankincense are the pentacyclic triterpenoids [7,55].

The major active components of frankincense are the boswellic acids (BA), which are extracted from the woody parts of different Boschella trees. The representative phytochemicals are β-boswellic acid, acetyl-β-boswellic acid (ABA), 11-keto-β-boswellic acid (KBA), 3-acetyl-11-keto-β-boswellic acid (AKBA), α-boswellic acid, and acetyl-α-boswellic acid. Figure 2 shows the chemical structure of the main BA.

The chemical composition and yield vary according to different factors such as the geographical region of the tree, the wood surface area, the collection season, the collection method, the age of the tree, and the storage conditions [56]. For instance, the gum resin from B. serrata has relatively similar quantities of 11-keto-β-boswellic acid (3–4.7%) and acetyl-11-keto-β-boswellic acid (2.2–2.9%) [7]. However, the resin from B. carterii contains 0.5% 11-keto-β-boswellic acid and 3.3% acetyl-11-keto-β-boswellic acid [7].

The gum resin of B. carterii reported from Somalia has α-thujene (19.2%), sabinenne (9.4%), limonene (7.8%), and α-pinene (7.2%) as the main constituents [57]. This is a native plant of the Red Sea region of North-East Africa, where it is abundant in Somalia and Ethiopia. Other studies on the composition of the oleo resin reported different components in different concentrations. For instance, Wahab reported that the oil contains 62.1% esters, 15.4% alcohols, 9.9% monoterpene hydrocarbons, and 7.1% diterpenes [58], and Wang et al. reported octyl acetate (60.0%), octanol (12.7%), and p-cymene (8.7%) [59]. The gas
chromatography–mass spectrometry (GC/MS) analysis of the hydro-distillate of B. carterii resin showed the presence of 40 different constituents. The major constituents were verticil (14.48%), isobutylcyclopentane (12.25%), n-octyl acetate (9.20%), and 9-oxabicyclo[6.1.0]-non-3-yn (9.12%) [60]. However, the composition of the resin differs due to different factors such as climate, geography, season of the year, and the extraction conditions. This notion is corroborated by a report from Chen et al. (2013) which observed low concentrations of the above components [61], while other studies reported higher concentrations of n-octyl acetate [61,62].

![Chemical structures](image)

**Figure 2.** Chemical structure of common boswellic acids found in frankincense. Two-dimensional chemical structures were obtained from Pub Chem. Pub Chem CIDs are as follows: α-boswellic acid, 637234; acetyl-α-boswellic acid, 15181201; β-boswellic acid, 168928; acetyl-β-boswellic acid (ABA), 11386458; 11-keto-β-boswellic acid (KBA), 9847548; 3-acetyl-11-keto-β-boswellic acid (AKBA), 11168203.

*Boswellia dalzielii*, which grows in West Africa, is an understudied species. However, a study conducted using essential oil from 21 oleoresin samples from northern Nigeria and two samples from Ghana revealed that α-pinene was the dominant component (21.7–76.6%), followed by α-thujene (2.0–17.6%), myrcene (up to 35.2%), p-cymene (0.3–15.6%), and limonene (1.1–32.9%) [63]. It was reported that out of the 29 compounds obtained from the essential oil from leaves, α-pinene was the dominant component (45.7%) [64]. On the other hand, it was also reported that out of 50 compounds isolated, δ-3-carene (27.7%) was the dominant one [65]. The most abundant chemical components and the type of *Boswellia* plant sources are summarized in Table 2.
Table 2. Prominent features of compounds in frankincense resin and oils.

| Frankincense Type | Country of Origin | Source | Chemical/Active Component                                                                 | References |
|-------------------|-------------------|--------|-------------------------------------------------------------------------------------------|------------|
| *Boswellia dalzielii* | Chad, Mali, Nigeria | Hydro-distilled leaf essential oil | δ-3-carene (27.7%), α-pinene (15.2%), p-cymene (9.5%), β-phellandrene (8.5%), isolongifolene (6.2%), and myrcene (5.7%). | [65] |
| *Boswellia dalzielii* | Nigeria | Hydro-distilled leaf essential oil | α-pinene (45.7%) and α-terpinene (11.5%), trans-sabinene hydrate (4.6%), cis-p-menth-2-en-1-ol (2.9%), α-campholenal (2.7%), caryophyllene oxide, and α-phellandrene (2.3%) | [64] |
| *B. carterii* | Somalia | Gum resin | Esters (62.1%), 1-octyl acetate being predominant (60.0%). Alcohols amount to 15.4%, 1-octanol being the major component (12.7%), and diterpene constituents amount to 7.1%, including cembrene (1.4%), isocembrene (1.8%), incensole (2.7%), and isoincensole (0.8) and a mixture of monoterpene hydrocarbons which amounts to 9.9%. | [58] |
| *B. rivae* | Ethiopia | Essential oil from frankincense | α-Pinene (36.1–67.7%), δ-3-carene (12.2%), and limonene (12.0%). | [66] |
| *B. neglecta* | Ethiopia | Essential oil from frankincense | α-Pinene (36.1–67.7%), terpinen-4-ol (11.3%). | [66] |

3. Modern Medicinal Uses of Frankincense

Many plant components from *Boswellia* are used to treat chronic diseases with comparatively few side effects [67,68]. Indian traditional medicine practice narrates that *Boswellia* decoctions were used to treat various gastrointestinal tract conditions such as diarrhea, flatulence, alimentary stoppage, and vomiting [69–72]. It was believed that the decoctions contain active ingredients from *Boswellia*, which are useful in treating the above-mentioned diseases. Furthermore, the extract was used to treat bronchitis, asthma, hoarseness, dyspnea, cough, and cold [73,74].

The gum extracts or resins from *Boswellia* sp. and their triterpenes, especially BA, have attracted the attention of pharmacologists, medicinal chemists, and biochemists as therapeutic agents due to their efficacy in treating rheumatoid arthritis and chronic inflammation without side effects and toxicity. The gum exudate obtained from the bark of the tree *B. serrata*, also called Indian olibanum, has been extensively used in the treatment of arthritis, asthma, ulcers, and skin diseases by practitioners of Indian traditional medicine [48,58]. It has also been widely used in various formulations for the treatment of inflammation related disorders in the past decade [48,75]. One study analyzed the effects of gum resins of *B. serrata* (900 mg daily divided in three doses for 6 weeks) on human patients suffering from chronic colitis [67,76]. The authors found that out of 20 patients treated with *Boswellia* gum resin, 18 patients showed an improvement in one or more parameters, including stool properties, histopathology and scanning electron microscopy characterization, hemoglobin, serum ion, calcium, phosphorus, proteins, total leukocytes, and eosinophils [67,76]. The control group (10 patients) was given sulfasalazine at a dose of 1 g three times a day for 6 weeks. The authors reported that 6 out of 10 patients in the control group showed similar improvements with the same parameters tested in the *B. serrata* group. This study demonstrates that a gum resin preparation from *B. serrata* might be effective in the treatment of chronic colitis, with minimal side effects [67,76]. The same research group evaluated the effects of *B. serrata* gum resin on the treatment of patients with bronchial asthma [74]. Their data demonstrated that 70% of patients treated with 300 mg thrice daily for 6 weeks showed improvement of disease, evident by the disappearance of physical symptoms and signs such as dyspnea, rhonchi, number of attacks, as well as
a decrease in eosinophilic counts. The control group (treated with placebo) only showed 27% of improvements in symptoms [74]. These data imply that gum resin from *B. serrata* could serve as a pharmacological agent in the treatment of bronchial asthma.

Gum resin from *B. serrata* was reported to be a potential remedy for inflammation, and it has been used as a folk medicine for topical and systemic inflammatory diseases for centuries [48]. The oleo gum resin of *B. carterii* has been used in folk medicine to treat cough and asthma and as an embalming fluid for human corpses. In addition, it has been used as an incense, respiratory antiseptic, and diuretic stimulant [58].

The oleo gum resin of *B. serrata* and *B. carterii* were also used in traditional medicine in different countries to treat rheumatic and other inflammatory diseases, including Crohn’s disease and ulcerative colitis [76–78]. However, *B. serrata* was reported to be the least effective in recurrent infections [79]. In addition, frankincense extracts and oils were used as antiseptic agents in mouthwash and also used to treat cough and asthma [77]. Furthermore, recent studies on animals and humans have demonstrated the efficacy of resin gum of *B. serrata* to treat inflammatory bowel disease, asthma, osteoarthritis, and rheumatoid arthritis [76,80,81].

Though frankincense has been known for its medicinal properties since antiquity, it is still widely used in modern medical treatment. In 2010, Moussaieff and Mechoulam reviewed *Boswellia* resin constituents in vitro, in vivo, and in clinical trials studies [82]. Indeed, in Ayurvedic medicine, different parts of the *Boswellia* tree and derived extracts are used for the treatment of respiratory, gastrointestinal, immune system, and skin conditions. Most of the published work focuses on the pharmacological activities of boswellic acids, specifically on their anti-inflammatory, analgesic, and anti-arthritic properties. As an example, there is growing evidence to support the clinical efficacy of *Boswellia* in osteoarthritis patients. However, there is inadequate evidence to demonstrate the clinical efficacy in rheumatoid arthritis patients [83]. The application of frankincense to treat different diseases of recent times is discussed below and summarized in Figure 3. Frankincense has been used to treat both infections and chronic diseases.

![Figure 3. Modern medicinal uses of *Boswellia*.](image-url)
3.1. Anti-Cancer

BA is one of the most extensively studied naturally occurring anti-cancer agents due to its anti-carcinogenic, anti-tumor, and anti-hyperlipidemic activities [4,84]. An in vitro study isolated five terpenoids from the gum resin of *B. carterii* and showed that three different compounds exhibited moderate cytotoxic effects against three human cancer cell lines [85]. The isolated compounds (named compounds 1–5) were chemically characterized, and their IC50 values against all three cell lines were described in the study [85]. Among the five compounds, compound 3 showed the following IC50 values: 49.84 ± 3.23 µM (against HepG2 cells, human hepatocellular carcinoma), 57.05 ± 7.85 µM (against A549 cells, human lung carcinoma), and 75.49 ± 7.80 µM (against MCF-7 cells, human breast cancer) [85]. All these values can be compared with IC50 for cisplatin (a chemotherapy drug used to treat several types of tumors): 23.44 ± 3.30 µM (against HepG2 cells), 18.32 ± 3.55 µM (against A549 cells), and 21.42 ± 7.57 µM (against MCF-7 cells) [85]. Even though compound 3 showed promising results, cisplatin was still more effective against the human cancer cell lines. Future studies might determine if the cisplatin and frankincense compounds have synergistic cytotoxic effects against human cancer cells.

AKBA and KBA are the key players involved in the cytotoxic effects of BAs. They inhibit topoisomerase I and IIa, which results in the inhibition of cell growth and proliferation by inducing apoptosis via a caspase-8-dependent pathway in human leukemia, colon, hepatoma, and in various other cancer cell lines in vitro [86,87]. IC50 values for boswellic acid essential oils were calculated and showed that essential oil hydro-distilled at 100 °C produced more potent cytotoxic effects [86]. The IC50 values for T47D cells were 900 and 1450 dilutions for essential oils obtained at 78 °C and 100 °C, respectively. Among the cancer cell lines tested in this study, MCF-7 cells were the most sensitive to essential oils with suppressed cell viability [86]. Boswellic acid acetate inhibited cell growth in vitro in a dose-dependent manner with IC50s of 5.8, 8.7, 7.3, 6.2, 9.8, and 6.6 µg/mL in NB4, SKNO-1, HL-60, U937, K562, and ML-1 cells at 4 days of treatment, respectively [87].

BAs also inhibit protein synthesis by interacting with ribosomal proteins, and thus control cancer development [88]. A study using human colon cancer cells in vitro suggested that *B. serrata* extracts inhibit proliferation, angiogenesis, and migration, and induces apoptosis of the cells by decreasing PGE2 levels [89].

3.2. Hypolipidemic and Hypoglycemic Effects

Animal studies have shown that the water-soluble fraction of *Boswellia* is effective in reducing the total cholesterol levels [90]. Extracts of *B. serrata* gum resins can reduce serum cholesterol levels and increase heavy-density lipoproteins (HDL) in rats [90]. In another study, *Boswellia* extracts significantly increased blood HDL levels and, remarkably, decreased blood low-density lipoprotein (LDL) levels, as well as the levels of liver enzymes SGPT and SGOT in patients after six weeks of treatment with *Boswellia* [91]. In contrast, the use of *B. serrata* gum resin for eight weeks at a relatively high dose did not lower glucose and lipid levels in diabetic patients [92].

Several studies have revealed that *Boswellia* gum resin has high hypolipidemic and hypoglycemic effects. Both BA and KBA reduced hyperglycemia and improved biochemical parameters such as the lipid profile. The strong anti-diabetic activity of β-BA and β-KBA was shown by treatments with different concentrations (1, 2, and 10 mg/kg body weight) for 21 days. This treatment significantly improved body weight loss, water consumption, and the concentration of blood glucose levels in diabetic animals [93]. Azemi et al. suggest that the use of appropriate doses of *B. serrata* extracts is vital in obtaining an anti-hyperglycemic effect on blood sugar and also in preventing complications of diabetes [94].

The effect of *Boswellia* resin on metabolic syndromes has been recently reviewed [95]. The extensive literature analysis of animal and human studies revealed that the resin’s protective and therapeutic effects are due to a decrease in hyperglycemia, hyperlipidemia, hypertension, and obesity. The authors refer the readers to this recent review for more details on the proposed mechanisms involved [95].
4. Antimicrobial Activity of Frankincense

In general, the bioactive natural compounds produced by different plants are considered better alternatives to synthetic antimicrobial and antioxidant agents. Different compounds obtained from Boswellia resins, particularly BA and their derivatives, exhibited diverse biological activities. As considered in this section, the antimicrobial effects can vary depending on the study and the amount of bioactive compounds present in the frankincense extracts.

4.1. Activity of Boswellia against Microbes

A study analyzed the antimicrobial and antioxidant activities of methanol extract, ethyl acetate extract, and essential oil from B. carterii resin [60]. The methanol extract exhibited the highest antimicrobial activity (MIC of 25 µg/mL) against different Gram-positive bacteria such as Bacillus subtilis, B. circulans, and Streptococcus faecalis, and a moderate MIC of 400 µg/mL against the Gram-positive Listeria monocytogenes, Gram-negative bacteria such as Escherichia coli (MIC of 25 µg/mL) and Pseudomonas aeruginosa (MIC of 300 µg/mL), and two yeasts, Candida albicans (MIC of >1000 µg/mL) and Saccharomyces cerevisiae (MIC of 25 µg/mL), compared with essential oil from B. carterii resin [60]. The ethyl acetate extract also showed favorable results, with MIC values ranging from 25 to >1000 µg/mL. The IC50 values for the methanol extract, ethyl acetate extract, and essential oils were 5.78, 7.66, and 15.21 mg/mL, respectively [60]. The methanol and ethyl acetate extracts displayed the highest antimicrobial activity against S. faecalis, B. subtilis, and B. circulans [60].

The antimicrobial activity of the essential oils obtained from the hydro distillation of the barks of B. dioscoridis, B. elongata, and B. socotrana were investigated against two Gram-positive (Staphylococcus aureus and B. subtilis) and two Gram-negative (E. coli and P. aeruginosa) bacterial species, as well as against C. albicans. The essential oils exhibited different levels of inhibition against the bacterial strains but not against C. albicans. The antimicrobial effects of the essential oils showed MIC of approximately 3–17 mg/mL compared with the use of conventional antibiotics (amoxicillin, gentamicin) and antifungals (nystatin) that showed MIC of approximately 3.5–7 µg/mL [96]. In general, Gram-positive strains exhibited higher susceptibility to the essential oils than Gram-negative strains. B. socotrana essential oil showed the highest antibacterial activity against S. aureus and B. subtilis [96].

The oleo gum resin essential oils from B. carterii (Somalia), B. papyrifera (Ethiopia), B. serrata (India), and B. riveae (Ethiopia) were individually tested against different fungi and Gram-positive and Gram-negative bacteria. The essential oils exhibited significant antifungal activity against both C. albicans and C. tropicalis, with the essential oils from B. carterii and B. papyrifera showing the best activity [97]. The MIC values for C. albicans and C. tropicalis were 12.86 and 12.86 µg/mL (B. serrata), 6.16 and 6.16 µg/mL (B. carterii), 6.09 and 6.09 µg/mL (B. papyrifera), and 2.65 and 27.38 µg/mL (B. riveae), respectively, compared with the MIC of 0.15 µg/mL for amphotericin B. The essential oil of B. riveae resin exhibited the best activity against C. albicans [97]. Limonene present in the essential oils is thought to be responsible for the antifungal activity [98], since oleo gum resin essential oils without limonene lack antifungal activity. The oleo gum resins also showed significant antibacterial effects against Gram-positive S. aureus and S. epidermidis, with MIC values ranging from 3.52 to 107.20 µg/mL. These values can be compared with the MIC of 1 µg/mL for vancomycin and 2 µg/mL for amikacin used as controls in the experiments [97]. The frankincense compounds against Gram-negative E. coli and P. aeruginosa showed MIC ranging from 6.60 to 107.18 µg/mL, compared to the vancomycin MIC of 10 and 5 µg/mL for E. coli and P. aeruginosa, respectively. It is noteworthy that some of the frankincense compounds had antimicrobial effects at concentrations that were comparable or very close to concentrations of the standard antibiotics used in the in vitro experiments. Future studies might confirm and expand the results to in vivo and clinical models.

Oils extracted from the resins of three B. sacra cultivars (Najdi, Sahli, and Houjri) were tested for their antimicrobial activities. Grade 1, grade 2, and grade 3 essential
Molecules 2022, 27, 4174

4.2. Activity of Boswellia against Fungal and Bacterial Biofilms

The structured microbial communities attached to a surface are called biofilms. Bacteria, fungi, and protists are capable of forming biofilms. S. aureus biofilms are the major cause of device-related infections, which are difficult to treat as the biofilms are generally resistant to conventional antibiotics [103]. Although less frequent, fungal films also develop on implanted medical devices. For instance, C. albicans, responsible for causing infections related to indwelling medical devices, is difficult to treat when it forms biofilms because of resistance against most antifungal agents [104,105]. Hence, there is a need to develop new antifungal agents, especially those that target the biofilm stage of the fungi.

B. papyrifera and B. ricae essential oils were tested against bacterial biofilms. B. papyrifera essential oil showed substantial activity against biofilms formed by both S. epidermidis and S. aureus. The essential oil of B. papyrifera also demonstrated noticeable antimicrobial effects on S. epidermidis biofilms. Similarly, B. ricae essential oil was effec-
tive against preformed *C. albicans* biofilms [106]. The essential oils especially inhibited germ tube formation and thus hyphal formation. The hyphal formation is vital for the virulence, biofilm formation, and structural integrity of *C. albicans* [105,107]. A large part of the inhibitory activity of *B. rivae* oleo gum resin oil was shown to be due to the presence of limonene (28%). Hence, further studies are warranted to characterize the antibiofilm activity of other components in the oleo gum resin oil.

### 4.3. Antimicrobial Activity against Oral Pathogens

Dental caries and periodontitis remain two of the major oral diseases that affect more than half of the global population [108]. Periodontitis is often referred as a common inflammatory disease in humans. Figure 4 shows oral cavities with and without periodontitis. The etiology of these diseases has been linked to certain bacterial species, plaque and biofilm formation, and the resultant inflammatory states. Current therapies for treating periodontal disease place an emphasis on biofilm removal. This is exercised via a combination of mechanical (such as scaling and root planing) and antibiotic treatments. However, these treatment modalities are still unable to fully remove biofilms. This has led to an interest in incorporating herbal extracts into current treatment regimens.

![Comparison of healthy and unhealthy gingival tissue. The healthy gingiva is pink in color, while unhealthy gingiva is darker red, and may present bleeding. (Photos from Pixabay.com and Wikipedia.org.)](image-url)

Many studies have been performed using the resin of *B. serrata*. As noted above, this resin contains boswellic acid, which are the active components in its anti-inflammatory effects. In addition, both the boswellic acid and the essential oils of *B. serrata* exhibit antimicrobial properties. Of the four major boswellic acids, acetyl-11-keto-β-boswellic acid (AKBA), has consistently demonstrated the greatest antibacterial effects. In fact, several studies have determined that AKBA is the most active component in the resin of *B. serrata* and other *Boswellia* species [109].

In terms of antibacterial effectiveness, AKBA isolated from *B. serrata* demonstrated activity against *Streptococcus mutans*, *Enterococcus faecalis*, *Enterococcus faecium*, *Actinomyces viscosus*, *Streptococcus sanguinis*, *Fusobacterium nucleatum*, *Prevotella intermedia*, and *Porphyromonas gingivalis*. Furthermore, the post-antibiotic effects of AKBA were determined to be greater than those of ciprofloxacin, and AKBA was also shown to inhibit biofilms of the cariogenic bacteria *S. mutans* [109].

In a double-blinded, randomized clinical trial, the effectiveness of traditional scaling and root planing methods were compared to the use of *B. serrata* extract or powder [110]. The results indicated that the addition of *B. serrata* extract or powder to traditional scaling and root planing treatments leads to better gingival health as measured by gingival, plaque, and bleeding indices, as well as probed pocket depths [110]. The authors concluded that the anti-inflammatory properties of *B. serrata* extract had results comparable or even superior to traditional scaling and root planing treatments.
In another study contrasting the potencies of different forms of frankincense extract, it was shown that hydro-alcoholic extract from B. serrata had greater antimicrobial potency than organic extract [111]. While the hydro-alcoholic extract could successfully inhibit C. albicans, S. mutans, C. krusei, and C. glabrata, organic extract could only inhibit C. glabrata at a higher concentration than was needed for the hydro-alcoholic extract.

Current periodontal therapies have often utilized synthetic chemical agents, most notably chlorhexidine, as adjunct to mechanical debridement. However, chronic use of such chemical agents can lead to undesirable side effects, including toxicity to connective tissue, staining, dysgeusia, dry mouth, and allergies [112]. Vahabi et al. analyzed the effects of B. serrata, L. inermis, and M. sylvestris on Aggregatibacter actinomycetemcomitans, one of the major species implicated in aggressive periodontitis, as possible alternatives to chlorhexidine. Of the three plant extracts, B. serrata had the strongest antimicrobial effect [112]. However, its effects were still inferior to those of chlorhexidine and doxycycline. The antimicrobial effects of frankincense against oral pathogens are summarized in Table 3. According to the data summarized in Table 3, AKBA showed stronger antimicrobial effects against oral pathogens (P. gingivalis, P. intermedia, E. faecalis, S. mutans, E. faecium, A. viscosus, S. sanguinis). Therefore, future studies should further examine the antimicrobial effects of AKBA on oral pathogens. Given its antibacterial, antifungal, and antioxidant properties, it is not surprising that frankincense also has promising beneficial effects on oral health.

There is growing evidence that BA is a multitarget agent, since it can modulate several molecular targets, such as enzymes, growth factors, kinases, transcription factors, receptors, and other targets related to survival and proliferation of cells [68]. However, to the best of our knowledge, it remains to be determined whether BA affects molecular targets specific to oral tissues that could affect oral microbial infection and diseases. Some of the molecular targets involved in anti-inflammatory diseases affected by BA will be discussed in the next section.

Table 3. Boswellic acid extracts or chemical constituents with antimicrobial activity against oral pathogens in vitro.

| Microbe                                  | Extract or Chemical Constituent | MIC (µg/mL) | References |
|------------------------------------------|---------------------------------|-------------|------------|
| Aggregatibacter actinomycetemcomitans ATCC 33384 (Gram-negative) | Boswellia serrata               | 512         | [113]      |
| Aggregatibacter actinomycetemcomitans JP2 NOV99 (Gram-negative) | HAE of Boswellia serrata        | 78          | [112]      |
| *Streptococcus mutans* ATCC 25175 (Gram-positive) |                                |             |            |
|                                            | KBA                             | 16          |            |
|                                            | AKBA                            | 2           |            |
|                                            | BA                              | 32          | [109]      |
|                                            | ABA                             | >128        |            |
| *Streptococcus mutans* PTCC 1688 (Gram-positive) |                                | 50,000      | [111]      |
| *Enterococcus faecalis* ATCC 29212 (Gram-positive) |                                |             |            |
|                                            | KBA                             | 16          |            |
|                                            | AKBA                            | 4           | [109]      |
|                                            | BA                              | 8           |            |
|                                            | ABA                             | >128        |            |
| *Enterococcus faecium* ATCC 8042 (Gram-positive) |                                |             |            |
|                                            | KBA                             | 16          |            |
|                                            | AKBA                            | 4           | [109]      |
|                                            | BA                              | 8           |            |
|                                            | ABA                             | >128        |            |
| *Actinomyces viscosus* ATCC 15987 (Gram-positive) |                                |             |            |
|                                            | KBA                             | 8           | [109]      |
|                                            | AKBA                            | 2           |            |
|                                            | BA                              | 64          |            |
|                                            | ABA                             | >128        |            |
Table 3. Cont.

| Microbe                                      | Extract or Chemical Constituent | MIC (µg/mL) | Reference |
|----------------------------------------------|---------------------------------|-------------|-----------|
| *Streptococcus sanguinis* ATCC 10556 (Gram-positive) | KBA                             | 8           |          |
|                                              | AKBA                            | 2           | [109]     |
|                                              | BA                              | 128         |           |
|                                              | ABA                             | >128        |           |
| *Fusobacterium nucleatum* ATCC 10953 (Gram-negative) | KBA                             | >128        | [109]     |
|                                              | AKBA                            | >128        |           |
|                                              | BA                              | >128        |           |
|                                              | ABA                             | >128        |           |
| *Prevotella intermedia* ATCC 25611 (Gram-negative) | KBA                             | 16          | [109]     |
|                                              | AKBA                            | 4           |           |
|                                              | BA                              | 32          |           |
|                                              | ABA                             | >128        |           |
| *Porphyromonas gingivalis* ATCC 33277 (Gram-negative) | KBA                             | 8           | [109]     |
|                                              | AKBA                            | 4           |           |
|                                              | BA                              | 32          |           |
|                                              | ABA                             | >128        |           |
| *Candida albicans* PTCC 5027 HAE of *Boswellia serrata* | HAE                             | 50,000      | [111]     |

MIC: minimum inhibitory concentration; KBA: 11-keto-β-boswellic acid; AKBA: acetyl-11-keto-β-boswellic acid; BA: β-boswellic acid; ABA: acetyl-β-boswellic acid; HAE: hydro-alcoholic extract.

5. Anti-Inflammatory Effects of Frankincense

Many patients consuming non-steroidal anti-inflammatory drugs (NSAID) suffer from adverse effects of the drugs on the gastrointestinal or cardiovascular systems. Many efforts have been made to develop drugs that avoid these complications, but the goal is still far from being achieved. Hence, it is necessary to search for novel, alternative drugs. In this context, *B. serrata* and other *Boswellia* species have gained prominence as potential alternatives as anti-inflammatory herbal remedies. The anti-inflammatory properties of boswellic acids have been well-established by several studies with cells in vitro, and preclinical, and clinical trials [4,7].

Studies on animals and humans have shown the anti-inflammatory potential of *B. serrata* gum resin to treat different inflammatory disorders such as inflammatory bowel disease, rheumatoid arthritis, osteoarthritis, and asthma [80]. Corticosteroids are essential to control cerebral edema but they also cause severe negative impacts. In contrast, the gum resin of *B. serrata* was found to control the peritumoral brain edema associated with glioma [114].

The anti-inflammatory activity of *B. serrata* is due to the presence of α- and β-boswellic acid and other pentacyclic triterpenic acids. These compounds inhibit pro-inflammatory processes by acting on 5-lipoxygenase and cyclo-oxygenase and on the complement system [73,115,116]. Inhibition of prostaglandin synthesis plays only a minimal role in the anti-inflammatory effect of BAs. However, inhibition of 5-lipoxygenase by BA decreases production of leukotrienes, whereas chronic inflammatory diseases are associated with increased leukotriene activity [115].

BA is involved in the inhibition of inflammation induced by factors such as histamine, prostaglandins, leukotriene, 5-lipoxygenase, human leukocyte elastase, cytokines, tumor necrosis factor, and free oxygen radicals. Figure 5 summarizes the inhibitory effects induced by BAs. To demonstrate the anti-inflammatory activity of the gum resin of *Boswellia* species, experiments were conducted in animal models. Carrageenan-induced mouse paw edema and rat pleurisy models were employed to test the effectiveness of defined BAs in vivo. This study also demonstrated the suppression of PGE\textsubscript{2} formation by BAs via interference with mPGES1, which may represent a biochemical basis for the anti-inflammatory effectiveness of BAs [117].
Some limitations of this study must be considered. First, more studies are required to elucidate the antimicrobial and anti-inflammatory mechanisms exerted by frankincense extracts and compounds. Secondly, more studies, including pre-clinical and randomized clinical trials, are needed to better understand the beneficial effects of frankincense extracts and compounds on human health. For more details on the pre-clinical and clinical activities of frankincense, we refer the readers to the recent reviews by Efferth and Oesch [4] and by Hussain et al. [118].

To the best of our knowledge, some limitations to large-scale application of frankincense compounds for clinical studies could be the lack of efficiency in the synthetic methodology for industrial production, and the sustainability of growing enough *Boswellia* trees [118]. According to Groenendijk et al. [119], over the next five decades, the population of *B. papyrifera* trees will decrease to about 10% of its present population due to over-exploitation in harvesting the tree [118].

6. Concluding Statement

*Boswellia* trees and natural products derived from the trees have been used since antiquity for the treatment of chronic disease, inflammation, and infection. The identification of the bioactive components of frankincense will allow the characterization of the molecular and cellular basis for their therapeutic effects, and the incorporation of these compounds into products that could be marketed for use in treatment for cancer and inflammation and improvement of oral health.

This review highlights the chemical compounds (boswellic acids) isolated from *Boswellia* gum resins and their potential antimicrobial, anti-tumor, and anti-inflammatory effects. The beneficial role of *Boswellia* gum resins in treating chronic diseases, such as colitis and bronchial asthma, in small studies including human patients, demonstrate the potential of frankincense for treatment in the clinical setting. However, more studies including a higher number of subjects and clinical trials are needed to confirm and expand our knowledge of the use of frankincense for treatment of chronic diseases.

Furthermore, this review discussed the antimicrobial effects of several active compounds of frankincense. Given the high cost of antibiotic therapy and the increase in antibiotic resistance, more research is needed on the potential antimicrobial effects of natural products. We focused on the most recent discoveries of the beneficial effects of frankincense compounds against oral pathogens, given the important connection between oral and systemic health [17].

Gum resin of *Boswellia* is included in the list of substances Generally Recognized As Safe (GRAS), which allows its use as a food additive by the U.S. FDA [109]. One could
easily envision the incorporation of frankincense and some of its components such as BAs into mouthwashes and toothpaste, and into topical ointments for inflammatory disorders of the skin.

**Author Contributions:** Conceptualization, C.L.C.A.-d.-S., N.S., M.W.Q., D.M.O. and M.M.E.; Writing—original draft, C.L.C.A.-d.-S., N.S. and A.C.-C.; Figure preparation, C.L.C.A.-d.-S.; Writing—review and editing, H.A., M.W.Q., D.M.O. and M.M.E. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was supported by intramural funds from the University of the Pacific to DMO and CLCAS (Start-Up Funds D30059—Activity 101).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Acknowledgments:** The figures were prepared using BioRender.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Yu, D.; Ryu, K.; Zhi, S.; Otto, S.J.G.; Neumann, N.F. Naturalized *Escherichia coli* in Wastewater and the Co-evolution of Bacterial Resistance to Water Treatment and Antibiotics. *Front. Microbiol.* 2022, 13, 810312. [CrossRef] [PubMed]

2. Ventola, C.L. The antibiotic resistance crisis: Part 1: Causes and threats. *Pharm. Ther.* 2015, 40, 277–283.

3. Al-Yasiry, A.R.; Kiczorowska, B. Frankincense—Therapeutic properties. *Postepy Hig. Med. Dos. (Online)* 2016, 70, 380–391. [CrossRef] [PubMed]

4. Efferth, T.; Oesch, F. Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities. *Semin. Cancer Biol.* 2022. [CrossRef] [PubMed]

5. Van Wyk, B.E. A review of commercially important African medicinal plants. *J. Ethnopharmacol.* 2015, 176, 118–134. [CrossRef]

6. Eslamieh, J. *Cultivation of Boswellia*, 2nd ed.; A Book’s Mind: Fort Collins, CO, USA, 2017.

7. Abdel-Tawab, M.; Werz, O.; Schubert-Zsilavecz, M. *Boswellia serrata*: An overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. *Clin. Pharmacokinet.* 2011, 50, 349–369. [CrossRef]

8. Britannica, The Editors of Encyclopaedia. Frankincense. Available online: https://www.britannica.com/topic/frankincense (accessed on 21 February 2022).

9. Bokelmann, J.M. Medicinal Herbs in Primary Care: An Evidence-Guided Reference for Healthcare Providers. In *Frankincense/Boswellia (Boswellia serrata/sacra/carterii): Bark Resin*; Bokelmann, J.M., Ed.; Medicinal Herbs in Primary Case; Elsevier: Amsterdam, The Netherlands, 2021; pp. 351–360.

10. The World Flora Online. 2022. Available online: http://www.worldfloraonline.org/ (accessed on 21 May 2022).

11. Al-Harrasi, A.; Khan, A.L.; Asaf, S.; Al-Rawahi, A. Taxonomy, Distribution and Ecology of *Boswellia* for the estimation of boswellic acids from the market formulations containing *Boswellia serrata* extract. *J. Chromatogr. Sci.* 2008, 46, 735–738. [CrossRef]

12. Shah, S.A.; Rathod, I.S.; Suahagia, B.N.; Pandya, S.S.; Parmar, V.K. A simple high-performance liquid chromatographic method for the estimation of boswellic acids from the market formulations containing *Boswellia serrata* extract. *Clin. Pharmacokinet.* 2011, 50, 349–369. [CrossRef] [PubMed]

13. Chemvier, M.R.; Ryan, A.E.; Lee, D.Y.; Zhongze, M.; Wu-Yan, Z.; Via, C.S. *Boswellia carterii* extract inhibits TH1 cytokines and promotes TH2 cytokines in vitro. *Clin. Diagn. Lab. Immunol.* 2005, 12, 575–580. [CrossRef]

14. Barnett, J.R.; Langenheim, J.H. Plant resins: Chemistry, evolution, ecology and ethnobotany. *Ann. Bot.* 2004, 93, 2. [CrossRef]

15. Hughes, L. The Funerals of the Russian Emperors and Empresses. In *Monarchy and Religion: The Transformation of Royal Culture in Eighteenth-Century Europe*; Schaich, M., Ed.; Oxford University Press: Oxford, UK, 2007; pp. 395–419.

16. Berhanu, Y.; Vedeld, P.; Angassa, A.; Aune, J.B. The contribution of frankincense to the agro-pastoral household economy and its potential for commercialization—A case from Borana, southern Ethiopia. *J. Arid Environ.* 2020, 186, 104423. [CrossRef]

17. Bui, F.Q.; Almeida-da-Silva, C.L.C.; Huynh, B.; Trinh, A.; Liu, J.; Woodward, J.; Asadi, H.; Ojcius, D.M. Association between periodontal pathogens and systemic disease. *Biomed. J.* 2019, 42, 27–35. [CrossRef] [PubMed]

18. The Word Flora Online. *Boswellia sacra* Flueck. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569724 (accessed on 21 May 2022).

19. The Word Flora Online. *Boswellia serrata* Roxb. Ex Colebr. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569726 (accessed on 21 May 2022).

20. The Word Flora Online. *Boswellia odorata* Hutch. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569716 (accessed on 21 May 2022).
21. The World Flora Online. *Boswellia popoviana* Hepper. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569719 (accessed on 21 May 2022).
22. The World Flora Online. *Boswellia ruspoliana* Engl. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569723 (accessed on 21 May 2022).
23. The World Flora Online. *Boswellia socotrana* Balf.f. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569727 (accessed on 21 May 2022).
24. The World Flora Online. *Boswellia holstii* Engl. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569705 (accessed on 21 May 2022).
25. The World Flora Online. *Boswellia microphylla* Chiov. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569709 (accessed on 21 May 2022).
26. The World Flora Online. *Boswellia multifoliolata* Engl. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569710 (accessed on 21 May 2022).
27. The World Flora Online. *Boswellia nana* Hepper. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569711 (accessed on 21 May 2022).
28. The World Flora Online. *Boswellia ogadensis* Vollesen. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569717 (accessed on 21 May 2022).
29. The World Flora Online. *Boswellia ovalifoliolata* N.P.Balakr. & A.N.Henry. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569718 (accessed on 21 May 2022).
30. The World Flora Online. *Boswellia prottiae* Chiov. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569720 (accessed on 21 May 2022).
31. The World Flora Online. *Boswellia aneeero* Balf.f. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569684 (accessed on 21 May 2022).
32. The World Flora Online. *Boswellia boranensis* Engl. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569688 (accessed on 21 May 2022).
33. The World Flora Online. *Boswellia bricchetii* (Chiov.) Chiov. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569689 (accessed on 21 May 2022).
34. The World Flora Online. *Boswellia bulbata* Thulin. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569690 (accessed on 21 May 2022).
35. The World Flora Online. *Boswellia chariensis* Guillaumin. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569695 (accessed on 21 May 2022).
36. The World Flora Online. *Boswellia dioscoridis* Thulin. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569697 (accessed on 21 May 2022).
37. The World Flora Online. *Boswellia elongata* Balf.f. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569699 (accessed on 21 May 2022).
38. The World Flora Online. *Boswellia freerana* Birdw. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569700 (accessed on 21 May 2022).
39. The World Flora Online. *Boswellia globosa* Thulin. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569703 (accessed on 21 May 2022).
40. The World Flora Online. *Boswellia dalzieli* Hutch. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569696 (accessed on 21 May 2022).
41. The World Flora Online. *Ambilobea madagascariensis* (Capuron) Thulin, Beier & Razafim. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000741637 (accessed on 21 May 2022).
42. The World Flora Online. *Garuga floribunda* Decne. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000694779 (accessed on 21 May 2022).
43. The World Flora Online. *Boswellia papyrifera* (Caill. Ex Delile) Hochst. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569719 (accessed on 21 May 2022).
44. The World Flora Online. *Boswellia rivae* Engl. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569722 (accessed on 21 May 2022).
45. The World Flora Online. *Boswellia hildebrandtii* Engl. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569702 (accessed on 14 June 2022).
46. The World Flora Online. *Boswellia elegans* Engl. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569698 (accessed on 17 June 2022).
47. The World Flora Online. *Boswellia neglecta* S.Moore. 2022. Available online: http://www.worldfloraonline.org/taxon/wfo-0000569712 (accessed on 21 May 2022).
48. Yuan, G.; Wahlqvist, M.L.; He, G.; Yang, M.; Li, D. Natural products and anti-inflammatory activity. *Asia Pac. J. Clin. Nutr.* 2006, 15, 143–152. [PubMed]
49. Jones, J.K.N.; Nunn, J.R. The Structure of Frankincense Gum. *J. Am. Chem. Soc.* 1955, 77, 5745–5746. [CrossRef]
77. Banno, N.; Akihisa, T.; Yasukawa, K.; Tokuda, H.; Tabata, K.; Nakamura, Y.; Nishimura, R.; Kimura, Y.; Suzuki, T. Anti-inflammatory activity of polysaccharide fractions from *Boswellia carterii* frankincense resin. *Int. J. Biol. Macromol.* 2019, 133, 76–85. [CrossRef]

50. Hosain, N.A.; Ghosh, R.; Bryant, D.L.; Arivett, B.A.; Farone, A.L.; Kline, P.C. Isolation, structure elucidation, and immunostimulatory activity of polysaccharide fractions from *Boswellia carterii* frankincense resin. *Int. J. Biol. Macromol.* 2019, 133, 76–85. [CrossRef]

51. Amri, A.S.L.; Jesil, A.; Salim, A.; Saravananam, A.M. Extraction of Essential Oil from Frankincense Using Steam Distillation. *Int. J. Trend Res. Dev.* 2019, 6, 3.

52. Siddiqui, M.Z. *Boswellia serrata*, a potential antiinflammatory agent: An overview. *Indian J. Pharm. Sci.* 2011, 73, 255–261. [CrossRef]

53. Wang, F.; Li, Z.L.; Cui, H.H.; Hua, H.M.; Jing, Y.K.; Liang, S.W. Two new triterpenoids from the resin of *Boswellia carterii*. *J. Asian Nat. Prod. Res.* 2011, 13, 193–197. [CrossRef]

54. Ren, P.; Ren, X.; Cheng, L.; Xu, L. Frankincense, pine needle and geranium essential oils suppress tumor progression through the regulation of the AMPK/mTOR pathway in breast cancer. *Oncol. Rep.* 2018, 39, 129–137. [CrossRef]

55. Shen, T.; Lou, H.X. Bioactive constituents of myrrh and frankincense, two simultaneously prescribed gum resins in chinese traditional medicine. *Chem. Biodivers.* 2008, 5, 540–553. [CrossRef]

56. Vuddanda, P.R.; Singh, S.; Velaga, S. Boswellic acid—Medicinal use of an ancient herbal remedy. *J. Herb. Med.* 2016, 6, 8. [CrossRef]

57. Chiavari, G.; Galletti, G.C.; Piccaglia, R.; Mohamud, M.A. Differentiation between Resins *Boswellia Carteri* and *Boswellia Fraenana* (Frankincense) of Somali Origin. *J. Essent. Oil Res.* 1990, 3, 2. [CrossRef]

58. Wahab, S.M.; Aboutabl, E.A.; El-Zalabani, S.M.; Foad, H.A.; De Pooter, H.L.; El-Fallah, B. The essential oil of olibanum. *Planta Med.* 1997, 53, 382–384. [CrossRef] [PubMed]

59. Wang, W.; Zhu, Y.; Liu, L.; Ding, D.; Qin, X.; Tian, J. Analysis of the Chemical Constituents of Essential Oil of *Boswellia Carteri* Birdwood from Somali. *Chin. J. Pharm. Anal.* 1993, 13, 3.

60. Mohamed, A.A.; Ali, S.I.; Kabiel, H.F.; Hegazy, A.K.; Kord, M.A.; EL-Baz, F.K. Assessment of Antioxidant and Antimicrobial Activities of Essential Oil and Extracts of *Boswellia Carteri* Resin. *Int. J. Pharmacogn. Phytochem. Res.* 2015, 7, 8.

61. Chen, Y.; Zhou, C.; Ge, Z.; Liu, Y.; Liu, Y.; Feng, W.; Li, S.; Chen, G.; Wei, T. Composition and potential anticancer activities of essential oils obtained from myrrh and frankincense. *Oncol. Lett.* 2013, 6, 1140–1146. [CrossRef]

62. Mikhaili, B.R.; Maarootq, G.T.; Badria, F.A.; Amer, M.M. Chemistry and immunomodulatory activity of frankincense oil. *Z. Nat. C Prod.* 2003, 58, 230–238. [CrossRef]

63. DeCarlo, A.; Johnson, S.; Okeke-Agulu, K.L.; Dosoky, N.S.; Wax, S.J.; Owolabi, M.S.; Setzer, W.N. Compositional analysis of the essential oil of *Boswellia Dalzielii* frankincense from West Africa reveals two major chemotypes. *Phytochemistry* 2019, 164, 24–32. [CrossRef]

64. Dimas Kubmarawa, I.A.O.; Okorie, D.A.; Olawore, N.O.; Kasali, A.A. Constituents of the Essential Oils of *Boswellia Dalzielii* Hutch. from Nigeria. *J. Essent. Oil Res.* 2011, 18, 2. [CrossRef]

65. Kohoude, M.J.; Gbaguidi, F.; Agbani, P.; Ayedoun, M.A.; Cazaux, S.; Bouajila, J. Chemical composition and biological activities of extracts and essential oil of *Boswellia Dalzielii* leaves. *Pharm. Biol.* 2017, 55, 33–42. [CrossRef]

66. De Rapper, S.; Van Vuure, S.F.; Kamatou, G.P.; Vlijmoen, A.M.; Dagene, E. The additive and synergistic antimicrobial effects of select frankincense and myrrh oils—A combination from the pharaonic pharmacopoeia. *Lett. Appl. Microbiol.* 2012, 54, 352–358. [CrossRef]

67. Gupta, I.; Parihar, A.; Malhotra, P.; Gupta, S.; Ludtke, R.; Safayhi, H.; Ammon, H.P. Effects of gum resin of *Boswellia serrata* in patients with chronic colitis. *Planta Med.* 2001, 67, 391–395. [CrossRef] [PubMed]

68. Roy, N.K.; Parama, D.; Banik, K.; Bordoloi, D.; Devi, A.K.; Thakur, K.K.; Padmavathi, G.; Shakibaei, M.; Fan, L.; Sethi, G.; et al. An Update on Pharmacological Potential of Boswellic Acids against Chronic Diseases. *Int. J. Mol. Sci.* 2019, 20, 4101. [CrossRef]

69. Iram, F.; Khan, S.A.; Husain, A. Phytochemistry and potential therapeutic actions of Boswellic acids: A mini-review. *Asian Pac. J. Trop. Biomed.* 2017, 7, 513–523. [CrossRef]

70. Padhi, M.; Mahapatra, S. *Boswellia serrata*: A review of its traditional uses, phytochemistry and pharmacology. *Int. Rev. Biophys. Chem. (IREBC)* 2013, 4, 74–83.

71. Catanzaro, D.; Rancan, S.; Orso, G.; Dell’Acqua, S.; Brun, P.; Giron, M.C.; Carrara, M.; Castagliuolo, I.; Ragazzi, E.; Caparrotta, L.; et al. *Boswellia serrata* Preserves Intestinal Epithelial Barrier from Oxidative and Inflammatory Damage. *PLoS ONE* 2015, 10, e0125375. [CrossRef]

72. Borrelli, F.; Capasso, F.; Capasso, R.; Ascione, V.; Aviello, G.; Longo, R.; Izzo, A.A. Effect of *Boswellia serrata* on intestinal motility in rodents: Inhibition of diarrhea without constipation. *Br. J. Pharmacol.* 2006, 148, 553–560. [CrossRef]

73. Ammon, H.P. Boswellic acids in chronic inflammatory diseases. *Planta Med.* 2006, 72, 1100–1116. [CrossRef]

74. Gupta, I.; Gupta, V.; Parihar, A.; Gupta, S.; Ludtke, R.; Safayhi, H.; Ammon, H.P. Effects of *Boswellia serrata* gum resin in patients with bronchial asthma: Results of a double-blind, placebo-controlled, 6-week clinical study. *Eur. J. Med. Res.* 1998, 3, 511–514.

75. Shah, B.A.; Qazi, G.N.; Taneja, S.C. Boswellic acids: A group of medicinally important compounds. *Nat. Prod. Rep.* 2009, 26, 72–89. [CrossRef]

76. Banno, N.; Akihisa, T.; Yasukawa, K.; Tokuda, H.; Tabata, K.; Nakamura, Y.; Nishimura, R.; Kimura, Y.; Suzuki, T. Anti-inflammatory activities of the triterpene acids from the resin of *Boswellia carteri*. *J. Ethnopharmacol.* 2006, 107, 249–253. [CrossRef] [PubMed]
99. Di Stefano, V.; Schillaci, D.; Cusimano, M.G.; Rishan, M.; Rashan, L. In Vitro Antimicrobial Activity of Frankincense Oils from

96. Mothana, R.A.A.; Hasson, S.S.; Schultze, W.; Mowitz, A.; Lindequist, U. Phytochemical Composition and in Vitro Antimicrobial

91. Ahangarpour, A.; Heidari, H.; Fatemeh, R.A.; Pakmehr, M.; Shahbazian, H.; Ahmadi, I.; Mombeini, Z.; Mehrangiz, B.H. Effect of

87. Xia, L.; Chen, D.; Han, R.; Fang, Q.; Wuxman, S.; Jing, Y. Boswellic acid acetate induces apoptosis through caspase-mediated

95. Mahdian, D.; Abbaszadeh-Goudarzi, K.; Raoofi, A.; Dadashizadeh, G.; Abroudi, M.; Zarepour, E.; Hosseinzadeh, H. Effect of

81. Krieglstein, C.F.; Anthoni, C.; Rijcken, E.J.; Laukotter, M.; Spiegel, H.U.; Boden, S.E.; Schweizer, S.; Safayhi, H.; Senninger, N.; Schurmann, G. Acetyl-11-keto-beta-boswellic acid, a constituent of a herbal medicine from Boswellia serrata resin, attenuates experimental ileitis. Int. J. Colorectal. Dis. 2001, 16, 88–95. [CrossRef]

92. Mehrzadi, S.; Tavakolifar, B.; Huseini, H.F.; Mosavat, S.H.; Heydari, M. The Effects of

89. Ranjbarnejad, T.; Saidijam, M.; Moradkhani, S.; Najafi, R. Methanolic extract of

88. Casapullo, A.; Cassiano, C.; Capolupo, A.; Del Gaudio, F.; Esposito, R.; Tosco, A.; Riccio, R.; Monti, M.C. Five terpenoids from the gum resin of

86. Suhail, M.M.; Wu, W.; Cao, A.; Mondalek, F.G.; Fung, K.M.; Shih, P.T.; Fang, Y.T.; Wooley, C.; Young, G.; Lin, H.K. Boswellic acids: Biological actions and molecular targets. Biofactors 2000, 13, 225–230. [CrossRef]

85. Feng, Y.; Zhang, Q.; Sun, L. Five terpenoids from the gum resin of Boswellia carterii and their cytotoxicity. Fitoterapia 2021, 154, 105017. [CrossRef]

84. Suhail, M.M.; Wu, W.; Cao, A.; Mondalek, F.G.; Fung, K.M.; Shih, P.T.; Fang, Y.T.; Woolley, C.; Young, G.; Lin, H.K. Boswellia sacra essential oil induces tumor cell-specific apoptosis and suppresses tumor aggressiveness in cultured human breast cancer cells. BMC Complement. Altern. Med. 2011, 11, 129. [CrossRef]

83. Xia, L.; Chen, D.; Han, R.; Fang, Q.; Waxman, S.; Jing, Y. Boswellic acid acetate induces apoptosis through caspase-mediated pathways in myeloid leukemia cells. Mol. Cancer Ther. 2005, 4, 381–388. [CrossRef] [PubMed]

82. Moussaieff, A.; Mechoulam, R. Inflamm. Bowel Dis. 2006, 12, 979–987. [CrossRef] [PubMed]

81. Poeckel, D.; Werz, O. Boswellic acids: Biological actions and molecular targets. Curr. Med. Chem. 2006, 13, 3359–3369. [CrossRef]

80. S. Afr. J. Bot. 2010, 76, 168–175. [CrossRef] [PubMed]

79. Holtmeier, W.; Zeuzem, S.; Freiss, J.; Kruijs, W.; Bohn, S.; Maaser, C.; Raeder, A.; Schmidt, C.; Schnitker, J.; Schwarz, J.; et al. Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn’s disease: Good safety profile but lack of efficacy. Inflamm. Bowel Dis. 2011, 17, 573–582. [CrossRef] [PubMed]

78. Langmead, L.; Rampton, D.S. Review article: Complementary and alternative therapies for inflammatory bowel disease. Aliment. Pharmacol. Ther. 2006, 23, 341–349. [CrossRef] [PubMed]

77. L. inhibits lipopolysaccharide induced nitric oxide production in rat macrophages along with hypolipidemic property. Indian J. Exp. Biol. 2005, 43, 509–516. [PubMed]

76. S. Afr. J. Bot. 2010, 76, 335–349. [CrossRef] [PubMed]

75. J. Pharm. Pharmacol. 2010, 61, 1281–1293. [CrossRef]

74. Krieglstein, C.F.; Anthoni, C.; Rijcken, E.J.; Laukotter, M.; Spiegel, H.U.; Boden, S.E.; Schweizer, S.; Safayhi, H.; Senninger, N.; Schurmann, G. Acetyl-11-keto-beta-boswellic acid, a constituent of a herbal medicine from Boswellia serrata resin, attenuates experimental ileitis. Int. J. Colorectal. Dis. 2001, 16, 88–95. [CrossRef]

73. Moussaieff, A.; Mechoulam, R. Boswellia resin: From religious ceremonies to medical uses; a review of in-vitro, in-vivo and clinical trials. J. Pharm. Pharmacol. 2010, 61, 105017. [CrossRef]

72. Pandey, R.S.; Singh, B.K.; Tripathi, Y.B. Extract of gum resins of Boswellia serrata L. inhibits lipopolysaccharide induced nitric oxide production in rat macrophages along with hypolipidemic property. Indian J. Exp. Biol. 2005, 43, 509–516. [PubMed]

71. Azemi, M.E.; Namjoyan, F.; Khodayar, M.J.; Ahmadpour, F.; Darvish Padok, A.; Panahi, M. The Antioxidant Capacity and Anti-diabetic Effect of Boswellia serrata Gum Resin on the Blood Glucose and Lipid Profile of Diabetic Patients: A Double-Blind Randomized Placebo-Controlled Clinical Trial. J. Evid. Based Integr. Med. 2018, 23, 2515690 × 18772728. [CrossRef] [PubMed]

70. Mehrzadi, S.; Tavakolifar, B.; Huseini, H.F.; Mosavat, S.H.; Heydari, M. The Effects of Boswellia serrata Gum Resin on the Blood Glucose and Lipid Profile of Diabetic Patients: A Double-Blind Randomized Placebo-Controlled Clinical Trial. J. Evid. Based Integr. Med. 2018, 23, 2515690 × 18772728. [CrossRef] [PubMed]

69. Azemi, M.E.; Namjoyan, F.; Khodayar, M.J.; Ahmadpour, F.; Darvish Padok, A.; Panahi, M. The Antioxidant Capacity and Anti-diabetic Effect of Boswellia serrata Gum Resin on the Blood Glucose and Lipid Profile of Diabetic Patients: A Double-Blind Randomized Placebo-Controlled Clinical Trial. J. Evid. Based Integr. Med. 2018, 23, 2515690 × 18772728. [CrossRef] [PubMed]

68. K. Natur. Pharm. Prod. 2012, 7, 168–175. [CrossRef]

67. Molecules 2020, 9, 195. [CrossRef] [PubMed]

66. Chao, S.; Young, G.; Obeg, C.; Nakaoaka, K. Inhibition of methicillin-resistant Staphylococcus aureus (MRSA) by essential oils. Flavour Fragr. J. 2008, 23, 6. [CrossRef]

65. El-Nagerabi, S.A.F.; Elshafei, A.E.; Alkhanjari, S.S.; Al-Bahry, S.N.; Elamin, M.R. Biological Activities of Boswellia Sacra Extracts on the Growth and Aflatoxins Secretion of Two Aflatoxigenic Species of Aspergillus Species. Food Control 2013, 34, 7. [CrossRef]
103. Gotz, F. Staphylococci in colonization and disease: Prospective targets for drugs and vaccines. *Curr. Opin. Microbiol.* 2004, 7, 477–487. [CrossRef]

104. Douglas, L.J. Candida biofilms and their role in infection. *Trends Microbiol.* 2003, 11, 30–36. [CrossRef]

105. Wesenberg-Ward, K.E.; Tyler, B.J.; Sears, J.T. Adhesion and biofilm formation of *Candida albicans* on native and Pluronic-treated polystyrene. *Biofilms* 2005, 2, 8. [CrossRef]

106. Schillaci, D.; Arizza, V.; Dayton, T.; Camarda, L.; Di Stefano, V. In vitro anti-biofilm activity of *Boswellia* spp. oleogum resin essential oils. *Lett. Appl. Microbiol.* 2008, 47, 433–438. [CrossRef]

107. Watnick, P.; Kolter, R. Biofilm, city of microbes. *J. Bacteriol.* 2000, 182, 2675–2679. [CrossRef] [PubMed]

108. Eke, P.I.; Borgnakke, W.S.; Genco, R.J. Recent epidemiologic trends in periodontitis in the USA. *Periodontology 2000* 2020, 82, 257–267. [CrossRef] [PubMed]

109. Raja, A.F.; Ali, F.; Khan, I.A.; Shawl, A.S.; Arora, D.S. Acetyl-11-keto-beta-boswellic acid (AKBA); targeting oral cavity pathogens. *BMC Res. Notes* 2011, 4, 406. [CrossRef] [PubMed]

110. Khosravi Samani, M.; Mahmoodian, H.; Moghadamnia, A.; Poorsattar Bejeh Mir, A.; Chitsazan, M. The effect of Frankincense in the treatment of moderate plaque-induced gingivitis: A double blinded randomized clinical trial. *Daru* 2011, 19, 288–294. [PubMed]

111. Bakhtiari, S.; Nematzade, F.; Hakemi-Vala, M.; Talebi, G. Phenotypic Investigation of the Antimicrobial Effect of Organic and Hydro-Alcoholic Extracts of *Boswellia serrata* on Oral Microbiota. *Front. Dent.* 2019, 16, 386–392. [CrossRef] [PubMed]

112. Vahabi, S.; Hakemi-Vala, M.; Gholami, S. In vitro Antibacterial Effect of Hydroalcoholic Extract of *Lawsonia inermis, Malva sylvestris*, and *Boswellia serrata* on *Aggregatibacter actinomycetemcomitans*. *Adv. Biomed. Res.* 2019, 8, 22. [CrossRef] [PubMed]

113. Maraghempour, B.; Khayamzadeh, M.; Najafi, S.; Kharaizad, M. Traditionally used herbal medicines with antibacterial effect on *Aggregatibacter actinomycetemcomitans: Boswellia serrata* and *Nigella sativa*. *J. Indian Soc. Periodontol.* 2016, 20, 603–607. [CrossRef]

114. Winking, M.; Sarikaya, S.; Rahmanian, A.; Jodicke, A.; Boker, D.K. Boswellic acids inhibit glioma growth: A new treatment option? *J. Neurooncol.* 2000, 46, 97–103. [CrossRef]

115. Ammon, H.P. Modulation of the immune system by *Boswellia serrata* extracts and boswellic acids. *Phytomedicine* 2010, 17, 862–867. [CrossRef] [PubMed]

116. Knaus, U.; Wagner, H. Effects of boswellic acid of *Boswellia serrata* and other triterpenic acids on the complement system. *Phytomedicine* 1996, 3, 77–80. [CrossRef]

117. Siemoneit, U.; Koeberle, A.; Rossi, A.; Dehm, F.; Verhoff, M.; Reckel, S.; Maier, T.J.; Jauch, J.; Northoff, H.; Bernhard, F.; et al. Inhibition of microsomal prostaglandin E2 synthase-1 as a molecular basis for the anti-inflammatory actions of boswellic acids from frankincense. *Br. J. Pharmacol.* 2011, 162, 147–162. [CrossRef] [PubMed]

118. Hussain, H.; Rashan, L.; Hassan, U.; Abbas, M.; Hakkim, F.L.; Green, I.R. Frankincense diterpenes as a bio-source for drug discovery. *Expert Opin. Drug Discov.* 2022, 17, 513–529. [CrossRef] [PubMed]

119. Groenendijk, P.; Eshete, A.; Sterck, F.J.; Zuidema, P.A.; Bongers, F. Limitations to sustainable frankincense production: Blocked regeneration, high adult mortality and declining populations. *J. Appl. Ecol.* 2011, 49, 164–173. [CrossRef]